BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29980790)

  • 21. Activation of the ER stress and calcium signaling in angiomyolipoma.
    Novotna B; Takacova M; Hudecova S; Lencesova L; Breza J; Misak A; Csaderova L; Pastorekova S; Krizanova O; Breza J
    Neoplasma; 2016; 63(5):687-95. PubMed ID: 27468872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
    Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
    Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel mTORC1 Mechanism Suggests Therapeutic Targets for COMPopathies.
    Posey KL; Coustry F; Veerisetty AC; Hossain MG; Gambello MJ; Hecht JT
    Am J Pathol; 2019 Jan; 189(1):132-146. PubMed ID: 30553437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells.
    Wang J; Filippakis H; Hougard T; Du H; Ye C; Liu HJ; Zhang L; Hindi K; Bagwe S; Nijmeh J; Asara JM; Shi W; El-Chemaly S; Henske EP; Lam HC
    Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34544857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress.
    Li X; Li M; Ruan H; Qiu W; Xu X; Zhang L; Yu J
    Oncotarget; 2017 Feb; 8(6):9280-9292. PubMed ID: 28030835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nelfinavir Induces Endoplasmic Reticulum Stress and Sensitizes Renal Cancer Cells to TRAIL.
    Okubo K; Sato A; Isono M; Asano T; Asano T
    Anticancer Res; 2018 Aug; 38(8):4505-4514. PubMed ID: 30061216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
    Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
    BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
    Chiu HW; Tseng YC; Hsu YH; Lin YF; Foo NP; Guo HR; Wang YJ
    Cancer Lett; 2015 Jan; 356(2 Pt B):762-72. PubMed ID: 25449439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
    Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
    Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tumor development.
    Wang L; Ni Z; Liu Y; Ji S; Jin F; Jiang K; Ma J; Ren C; Zhang H; Hu Z; Zha X
    Oncotarget; 2017 Aug; 8(33):54858-54872. PubMed ID: 28903387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
    Brem GJ; Mylonas I; Brüning A
    Gynecol Oncol; 2013 Feb; 128(2):383-90. PubMed ID: 23107612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased rates of cerebral protein synthesis measured in vivo in a mouse model of Tuberous Sclerosis Complex: unexpected consequences of reduced tuberin.
    Saré RM; Huang T; Burlin T; Loutaev I; Smith CB
    J Neurochem; 2018 Jun; 145(5):417-425. PubMed ID: 29364507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Dunner K; Huang P; Abbruzzese JL; McConkey DJ
    Cancer Res; 2005 Dec; 65(24):11658-66. PubMed ID: 16357177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous activation and inhibition of autophagy sensitizes cancer cells to chemotherapy.
    Chi KH; Wang YS; Huang YC; Chiang HC; Chi MS; Chi CH; Wang HE; Kao SJ
    Oncotarget; 2016 Sep; 7(36):58075-58088. PubMed ID: 27486756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies.
    Goda AE; Erikson RL; Sakai T; Ahn JS; Kim BY
    Mol Oncol; 2015 Jan; 9(1):309-22. PubMed ID: 25245324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability.
    Valvezan AJ; Turner M; Belaid A; Lam HC; Miller SK; McNamara MC; Baglini C; Housden BE; Perrimon N; Kwiatkowski DJ; Asara JM; Henske EP; Manning BD
    Cancer Cell; 2017 Nov; 32(5):624-638.e5. PubMed ID: 29056426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress.
    Sato A; Asano T; Okubo K; Isono M; Asano T
    Oncol Res; 2018 Mar; 26(2):323-332. PubMed ID: 28560953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing
    Klover PJ; Thangapazham RL; Kato J; Wang JA; Anderson SA; Hoffmann V; Steagall WK; Li S; McCart E; Nathan N; Bernstock JD; Wilkerson MD; Dalgard CL; Moss J; Darling TN
    Elife; 2017 Jul; 6():. PubMed ID: 28695825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
    Komatsu S; Moriya S; Che XF; Yokoyama T; Kohno N; Miyazawa K
    Biochem Biophys Res Commun; 2013 Jul; 437(1):41-7. PubMed ID: 23792097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
    Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
    Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.